The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study

By sjmartinez • November 26, 2022

Benjamin DJ, Chen S, Eldredge JB, Schokrpur S, Li D, Quan Z, Chan JW, Cummings AL, Daly ME, Goldman JW, Gubens MA, Harris JP, Onaitis MW, Zhu VW, Patel SP, Kelly K. The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study. JTO Clin Res Rep. 2022 Oct 29;3(12):100427. doi: 10.1016/j.jtocrr.2022.100427. PMID: 36426286; PMCID: PMC9679033.

Tags: Actionable mutations, chemotherapy, Driver mutations, General Internal Medicine, immune checkpoint inhibitors, Non–small cell lung cancer, Oncogenic driven, Publications

Alcohol-Associated Hepatitis: Short- and Long-Term Management

De La Torre SA Jr, Morcos M, Saab S, Shetty A. Alcohol-Associated Hepatitis: Short- and Long-Term Management. Dig Dis Sci. 2024 Nov 22. doi: 10.1007/s10620-024-08705-1.[...]

Population health strategies for health equity in chronic kidney disease management

Brown CO, Pham PC, Shah A, Dukkipati R, Shen J, Dai T, Raff EA, Kalantar-Zadeh K. Population health strategies for health equity in chronic kidney[...]

The urine protein/creatinine ratio as a reliable indicator of 24-h urine protein excretion across different levels of renal function and proteinuria: the TUNARI prospective study

Gutiérrez-Peredo GB, Montaño-Castellón I, Gutiérrez-Peredo AJ, Lopes MB, Tapioca FPM, Guimaraes MGM, Montaño-Castellón S, Guedes SA, da Costa FPM, Mattoso RJC, Filho JCBO, Norris KC,[...]